Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Serelaxin for right ventricular function in acute heart failure
2014-002257-19Phase 3Active
- Sponsor
- Fundación para la Investigación Biomédica del Hospital Universitario Ramón y Cajal
- Start
- Feb 2015
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of serelaxin in Acute Heart Failure (AHF) (2 arms), sponsored by Fundación para la Investigación Biomédica del Hospital Universitario Ramón y Cajal. Primary endpoints: Change in TAPSE from baseline to 8-12 hours after treatment and Change in TAPSE from baseline to 1 week follow-up. Started Feb 2015; status: active.
02
Drugs
serelaxin
03
Conditions
Acute Heart Failure (AHF)
Beyond the preview
Go deeper on 2014-002257-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-002257-19.